Detalles de la búsqueda
1.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34793719
2.
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Future Oncol
; 16(1): 4289-4301, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778074
3.
Palbociclib and Letrozole in Advanced Breast Cancer.
N Engl J Med
; 375(20): 1925-1936, 2016 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959613
4.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 373(3): 209-19, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26030518
5.
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Breast Cancer Res
; 18(1): 67, 2016 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27349747
6.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
7.
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Blood
; 120(5): 1095-106, 2012 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-22718837
8.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Blood
; 119(20): 4597-607, 2012 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22383795
9.
Intermittent oral coadministration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats.
Toxicol Pathol
; 42(2): 422-34, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-23651588
10.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 56(12): 3320-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25813205
11.
The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
Blood Rev
; 17(3): 153-62, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12818225
12.
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Pigment Cell Melanoma Res
; 27(4): 590-600, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24495407
13.
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Clin Cancer Res
; 18(2): 568-76, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22090362
14.
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Mol Cancer Ther
; 11(7): 1565-75, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22504949
15.
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Clin Cancer Res
; 17(6): 1591-602, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21278246
16.
Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Mol Cancer Ther
; 9(6): 1618-28, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20530712
17.
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Invest New Drugs
; 26(5): 483-8, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18425418
18.
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Cancer Res
; 68(10): 3785-94, 2008 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18483262
19.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood
; 111(3): 1060-6, 2008 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17962510
20.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
Blood
; 103(1): 347-52, 2004 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12969970
Resultados
1 -
20
de 20
1
Próxima >
>>